

IN THE NAME OF GOD

*A 42 y/o woman present with acute
pancreatitis due to hyper TG*

Presentation By Amir Hossein Shokravi
9th Aban 1401

Patients ID:

- 42 yrs. old woman
- Born & live in Shemiran
- Married – three children
- Work in Tailoring

Chief Complaint:

She was admitted with **abdominal pain** claiming to have recent Melena from 2 days ago along with and Nausea in 7/26



Pain was localized in **RUQ and LUQ** and **epigastric**

That radiated to Back

She experienced a Minor Trauma in her bathroom 2 days before admission

She had multiple Hx of **episodic epigastric pain** that were relieved with anti acid and herbal medicines

PMHx :

Hyper lipedemia

Gemfibrosil 300 TDS was started 6 yrs ago with no history of F/O But she discontinued Gemfibrosil after 3 yrs and had no replacement

Diabet mellitus Dx from 6 yrs ago

HTN from 2 m ago (under valsartan treatment)

H pylori infection (not documented)

Fatty liver

Family Hx:

- HTN in her mother
- Her father died with Burning
- No definite Hx of Hyperlepidemia in her Family
- Her brother has suspicious symptom of plantar burning But dose not have any lab data

Drug Hx :

H₂ blocker and PPI : PRN

Metformin 500 TDS

Gemfibrosil 300 TDS

Valsartan 80

Metronidazol

Amoxicilin

Herbal medicine



- **Habitual History:**

- Consumption of herbal medicine

- **Social History :**

- Passive smoker

Review of Systems

- Headache (-) Nausea & Vomiting (+) Visual problems (-)
- Weight changes (-) Appetite changes (+) Sexual problems (-)
- Skin: Pigmentation (-) Diaphoresis (-)
- Ears, nose, mouth: N1
- Cardiovascular: N1, Palpitation (-)
- Respiratory: N1
- Gastrointestinal: nausea + diarrhea(-) , Epigastric pain (+)
- Musculoskeletal: N1
- Neurological: N1
- Psychiatric: N1

Physical Examination

- **GENERAL APPEARANCE:**
 - 42 yrs. old woman , ill but not toxic
- **Vital Sign at time of presentation:**
 - BP: 120/80 mmHg
 - HR: 120 / min
 - T : 37.5
 - RR : 20
 - Sat : 95%

Physical Examination:

- BMI : 30
- Head & Neck: (mild conjunctival icter) and eye peripheral echymosis
- Thorax: NI
- Lungs : Clear
- Heart : Normal
- Abdomen : Generalized and special epigastric Tenderness+
- Guarding (-) HSM(-)
- Skin: No pigmentation or acantosis nigricans
- Europtive Xanthoma(-) or tuberous scelerosis-
- Extremities :
 - Upper : Normal
 - Lower : Normal
 - BISAP : 1 بدو پذیرش

TG	Chol	Ca	P	Amylase	Lipase
9150	930	13	9.8	313	175
8300	834	13.8	10.1	900	795
8100	503	11.9	11.3	959	731
3620	395	11	10.5	365	186
1638		10.1	11.5	58	45
1028		10	10.5	237	48
1224		6 7/29	9.8	145	32
966		5.9	8.9		
843		6	8.7		
621		5.1	7.3		
536		5.3	7		
651		5.3	6		

WBC	Hb	Plt	Cr	Na	K	BUN
15000	18	297	0.9	139	4	11
11600	16	343	0.8	139	3.9	12
15500	13.9	378	1.4	137	3.8	10
9000	5.8	231	3.6	137	4.2	22
8900	5.6	235	4.7	135	4	29
6800	6.2	214	4.5	137	4.3	31
10000	7.7	223	4.9	137	4.4	39
9900	8.1	197	3.8	139	3.9	39
9300	7.9	174	4.6		5	94

- Patient was admitted in GI service and began this orders:
- NPO
- Serum N/S 3500 / 24h
- Pantoprazol 40 BID
- M.S PRN
- Metro 500 BID
- Cipro 400 BID
- Imipenem 500 QID
- Endocrine consult
- Surgery Consult

Subject of Consultation & Clinical Notes

گزارشات کلینیکی و موضوع مشاوره

بیمار خانم ۶۰ ساله با سابقه H1N1 مثبت و علائم سرماخوردگی؛ تستهای مثبت

تستهای مثبت برای تشخیص و تشخیص تستهای مثبت برای تشخیص

تستهای مثبت برای تشخیص و تشخیص تستهای مثبت برای تشخیص

تستهای مثبت برای تشخیص و تشخیص تستهای مثبت برای تشخیص

Consultant Physician's Observation & Notes

مشاهدات و نظریات پزشک مشاور (خلاصه نظریات، تشخیص، توصیه ها)

تستهای مثبت برای تشخیص و تشخیص تستهای مثبت برای تشخیص

Hep - 1000 u/L (1) if TG > 1000

check PIT TDS (2)

check TG neg (3)

Icu add (4)

TG 14 (5)

(6)



250 cc / hr (1) Regular (2) if BS (200) (3) (4) (5) (6)

Date

Consultant Physician Name & Signature

نام پزشک مشاور و امضاء



BS	509	605	337
----	------------	-----	-----

Hepatitis	neg
ANA	1.838 +
Anti dsDNA	5.56 -

1401/7/27	
	SG :1015
u/a	Glu +3
	Ket+1

Mg	Uric acid	Alb	LDH	HDL	LDL
1.2	40	3.9	965	38	182
1.5	6	3	2017		125
		2.9	184		
		2			

PH	Pco2	Hco3	BE
7.46	41	29.4	5.9
7.46	41.5	29.4	5.9
7.26	44.1	19.11	-7.7
7.15	48.7	16.4	-12.3
7.24	32.5	13.5	-13
7.1	55.6	16.6	-8
7.28	40	18.2	-7
7.33	33	17.6	-15
7.1	30	11	-14
7.23	29.5	11.9	-15
7.26	36	15.7	-13

مرکز پزشکی آموزشی و درمانی ایت الله طالقانی
سونوگرافی

مشخصات بیمار: [Redacted]
نام پدر: محمدباقر
شماره پرگه: ۲۴۷۰۲۲
کد پذیرش: ۶۱۳۴۵۰۷
پزشک معالج: -
تاریخ: ۱۴۰۱/۰۷/۲۶
کد ملی: [Redacted]
بخش: کلوزالیتی تحت نظر سرارز
کد شناسایی: ۱۹۷۳۶۲۰

لطفاً درخواستی سونوگرافی کامل شکم و لگن

با سلام

در بررسی اولتراسونیک کبد با سایز نرمال و با اکوی افزایش یافته مطرح کننده (fatty liver grade II) است. حدود کبد منظم است. قطر مجاری صفراوی داخل و خارج کبدی بورید، پورت و ورید های هپاتیک طبیعی می باشند. کبه صفرا فاقه سنگ بوده، و شکل و ضخامت جدار طبیعی دارد. طحال (spleen span = 102 mm) و پانکراس با سایز و اکوی طبیعی مشاهده می شوند. ضایعه فضاگیر در احشای شکمی فوق مشاهده نگردید. در بررسی اولتراسونیک کلیه راست با ابعاد تقریبی 115 (11) mm و کلیه چپ با ابعاد تقریبی 108 (15) mm در موقعیت طبیعی دیده می شود.

ضخامت و اکوی کورتکس در هر دو کلیه طبیعی است. اکوی مدولا و سینوس کلیه ها طبیعی می باشد. حلتاس به تنوع وجود سنگ اندواری، هیدرونفروز و ضایعه فضاگیر و کیستیک در کلیه ها مشاهده نمی گردد. مثانه حاوی ادرار و فاقه ضایعه جدار و اینترلویمینال رویت شد. رحم با ابعاد 55*27 mm و با اکوی نرمال رویت شد. ضایعه پاتولوژیک در آدنکس ها رویت نشد. حایع آزاد در فضای شکم و لگن رویت نشد.



- Patient became worse during the first night of admission with abdominal distention and oliguria and enhanced abdominal pain
- On 7/27 the patient went under hemodialysis due to persistent anorexia and azotemia
- And as a result of hypotension and call for vasopressor drugs, CRRT was recommended which was started within a few hours.

The patient was also diagnosed with Acute pancreatitis and was under treatment with Insulin infusion and heparin

ESR	143
Pro calcitonin	68/02
CRP	51

Signature of Physician

Treatment Progress

Date

بکار ویزیت شد شرایط کار، اطلاعاتی در مورد سابقه زانیت sat دارد

۱۷/۸/۸

در روز یکشنبه در بیمارستان در طرح درمان است در ۵:۳۰ AM

5:30

Am

شماره با N.E در ۱۱۰ است تب دار است
۶۰

Bil → ۳۶ → ۳,۲ → ۳,۱ → ۴,۳

L.D = ۱۸

UBC { pH = ۷,۱۵
HCO3 = ۱۶,۴

ATT > ۱۲۰

INR = ۳,۱۷

WBC = ۱۵,۱۵
Hb = ۱۳,۹ ← ۱۶ ← ۱۸
plt = ۳۳۳

uric Acid = ۴۰

دانشگاه علوم پزشکی و خدمات بهداشتی درمانی شهید بهشتی
مرکز پزشکی آموزشی و درمانی آیت الله طالقانی

MRI



خدمت درخواستی: MR کلایا یو گرافی MRCP

پایه ما:

CBD با توجه به تجمع مایع و stranding به خوبی قابل بررسی نیست، در حد قابل رویت دیپلانسیون و ضایحه اتسادی در CBD دیده نمی شود.

افزایش ضخامت جداري دئودنوم احتمالاً reactive به تغییرات انتهایی اطراف دیده می شود.

مطری صفراوی داخل کبدی: نرمال بدون شراعی از تنگی یا دیپلانسیون یا نفخ پرشدگی

کبد صفرا: نرمال

توده کبدی یا صفراوی: دیده نشد.

ورید پورت: نرمال

وریدهای سوبرامبلیک: نرمال

شلف توده: رویت نشد.

کبد: نرمال

طحال: نرمال

هنرولزیسته و برجستگی پانکراس به همراه تجمع مایع شدید پری پانکراتیک و stranding اطراف مطرح کننده Acute pancreatitis مشاهده می شود.

- On 7/28 the patient was intubated following LOC and respiratory distress and admitted in ICU
- On 7/29 despite that CRRT was carried on, the patient became worse and **Abdominal compartment syndrom** was assumed with surgery consult.
- IAP : 30 (fully catheter)

یہ نرسنگ سکریننگ سیشن کا وقت ہے۔ اس وقت پر CRT کا وقت لیا گیا ہے۔


14/7/19

یہ نرسنگ سکریننگ سیشن کا وقت ہے۔ اس وقت پر CRT کا وقت لیا گیا ہے۔

11:00 PM

اعتبار 115/75 اور 125 SBP ہے۔ یہ نرسنگ سکریننگ سیشن کا وقت ہے۔ اس وقت پر CRT کا وقت لیا گیا ہے۔

BP 95/60 PR 117 CVP 11



plan: CRT
سنگینہ دہی اور نرسنگ سکریننگ سیشن کا وقت ہے۔ اس وقت پر CRT کا وقت لیا گیا ہے۔

10/1/19

یہ نرسنگ سکریننگ سیشن کا وقت ہے۔ اس وقت پر CRT کا وقت لیا گیا ہے۔

2:20 AM

BP 67/34 PR 107 ORSAT 98% mode = CMMV

CVP = 9

WBC	Hb	Plt	Cr	Na	K	BUN	Date
15000	18	297	0.9	139	4	11	7/26
11600	16	343	0.8	139	3.9	12	
15500	13.9	378	1.4	137	3.8	10	
9000	5.8	231	3.6	137	4.2	22	
8900	5.6	235	4.7	135	4	29	7/30
6800	6.2	214	4.5	137	4.3	31	
10000	7.7	223	4.9	137	4.4	39	
9900	8.1	197	3.8	139	3.9	39	
9300	7.9	174	4.6		5	94	8/1


TG	Chol	Ca	P	Amylase	Lipase
9150	930	13	9.8	313	175
8300	834	13.8	10.1	900	795
8100	503	11.9	11.3	959	731
3620	395	11	10.5	365	186
1638		10.1	11.5	58	45
1028		10	10.5	237	48
1224		6 7/29	9.8	145	32
966		5.9	8.9		
843		6	8.7		
621		5.1	7.3		
536		5.3	7		
651		5.3	6		

امضاء پزشک Signature of Physician	پیشرفت معالجات Treatment Progress	تاریخ Date
	علیه نقل و حرکت CART از حسیه به کبک نقل	۲۹/۷/۱۹
	برای این بیمار در حسیه نقل تمام اجزاء CART مغز به پورته و نوسید	۸:۱۲ PM
	با سوراخ در کبک هم گاس حاصل و در اینجا خواهد شد	
	یو در کبک سکر. سول CART از حسیه به کبک CART	۱۹/۷/۱۹
	تا آنکه کبک به تمام اجزاء پورته ۵.۷ و ۵.۷ داشته است و کبک در	۱۱:۵۵ PM
	CBC در کبک سکر و در حسیه CART سکر و کبک سکر	
	اعمال ۱۱۵/۶۵ و حسیه ۱۲۵ SBP نیز بر سر پورته سکر CART	
	و اجزاء کبک به کبک کبک و کبک کبک CART واقع کبک	
	رو کبک کبک کبک کبک کبک کبک کبک کبک کبک کبک	
	دولت سکر: CVP ۱۱ PR ۱۱۷ BP ۹۵/۶۰	
	mod CIVV ۹۷%	



reshte | F

Talaghani Radiology



10cm

- On 7/30 the patient was transferred to the OR for laparotomy and **Necrotizing pancreatitis** was confirmed


Date	۱۴۰۱/۰۷/۲۹	تاریخ	Second Assistant	کدک دوم	First Assistant	کمک اول - مریم	Surgeon	جراح پشگاهی - محمد
Assistant Nurse	پرستار کدک اسپیده		Nurse Of OP.Room	پرستار اتاق عمل	Kind Of Anesthesia	General نوع بی‌هوشی	Anesthetist	فیروزه - فیروزه
Kind Of Operation	<input type="checkbox"/> Hosp. <input type="checkbox"/> بستری <input type="checkbox"/> OPD <input type="checkbox"/> سرپایی		نوع عمل		End Time	۱۵:۱۵ ساعت خاتمه	Start Time	۱۲:۳۰ ساعت شروع
Pre - OP Diagnosis	تشخیص قبل از عمل: جسی							
Post - OP Diagnosis	تشخیص بعد از عمل:							
Type Of Operation	۴۰۱۸۹۰ قراردادن درن اطراف پانکراس برای پانکراتیت حاد ۴۰۱۹۰ روزکسیون یا دبریدمان پانکراس و بافت های مجاور پانکر							
Specimen	<input type="checkbox"/> Yes <input type="checkbox"/> No		<input type="checkbox"/> Yes <input type="checkbox"/> No		نمونه برداشته شده تعداد: <input type="checkbox"/> بله <input type="checkbox"/> خیر			
Procedure and Findings	شرح عمل و مشاهدات [Redacted]							
Referral	شماره گارها و نوار قبل از عمل و بطن از آن منطبق می باشد؟							

OPERATION REPORT SHEET

Continue _____

ادامه شرح عمل از صفحه قبل

بیمار خانم ۴۲ ساله مورد پانکراتیت که فشار خون وابسته به نور ای نگریں برده است و آنوریک بود که فشار داخل شکم ۳۰ داشت که با تشخیص کمپارتمان شکمی به اتاق عمل آورده شد.

پس از برپ و درب تحت استزی جنرال شکم با پرس مهلا این باز شد  ده از داخل شکم ساکن شد و پانکراتیت بیمار نکروزه کامل بود و تمام مزوی کلون و ناحیه رتروپریتونیک نیز درگیر بود نسیج نکروزه پانکراس تا حد امکان دبرید شد که حدود ۹۰ درصد از بافت پانکراس نکروزه بود و دبرید شد و با حدود ۲۰ لیتر سرم تستستوس داده شد که ترشحات ان


سکاف شد دو درن جهت تستستوس شکم تعبیه شد و روی شکم URINE BAG سوچور شد و بیمار به صورت OPEN ABDOMEN منتقل شد

دستور بعد از عمل _____

Post - PO. Prders _____



امضاء پزشک Signature of Physician	پیشرفت معالجات Treatment Progress	تاریخ Date
	بیمار در وضعیت بدیهه و سبب distention شکم و صورت های بالا با بند بستیم	۳۰ تیر ۱۳۹۸
	بیمار در حالت فاسیاتیوی و بیمار برای انجام فاسیاتیوی به اتاق	
	عمل ریت انجام شد بیمار با مخرج با سرنایت لوززان تحت عمل با لوزر لوسومی قرار گرفته است	
	حالا بیمار در حال ایست CRRT است و رهای بیمار را بستیم NG است و سگ	
	دارد ایستوبه ایست	
	$Bil \rightarrow T = 2,6 \rightarrow 3,2 \rightarrow 3,1 \rightarrow 4,3 \rightarrow 3,5 \rightarrow 1,9$ $\hookrightarrow D \qquad \qquad \qquad \hookrightarrow 1,9$	
	$\left\{ \begin{array}{l} pH = 7,23 \\ HCO_3 = 11,9 \\ PCO_2 = 29,5 \end{array} \right.$	
	$\left\{ \begin{array}{l} DT7 = 52 \\ DT = 15,6 \\ INr = 1,5 \end{array} \right.$	
	$\left\{ \begin{array}{l} WBC = 8,9 \\ Hb = 5,7 \\ Plt = 235 \end{array} \right.$	
	CV = 4,9	



بیمه روزی ۱۰۰۰۰ تومان است و بیمه سالانه ۳۰۰۰۰۰ تومان است

۱۲/۱/۱۳۹۱

Dr. Karam

BP 110/70 PR 112 STANW ۱۰۰ در دقیقه

دوره های بیماری که بیشتر به اعصاب قلب و ریه است و بیشتر به CRP ۱۲/۱/۱۳۹۱

تسمه نقره است، کل زخم باز است و سیم دستگیر کردن ندارد

۱۰۰/۱۲h ← NG


۱۰۰/۱۲h در ۱۰۰/۱۲h

۱۰۰/۱۲h ← V10

CRP 5-10

۱۰۰/۱۲h ← ۱۰۰/۱۲h

PH = 7.39	PT = 14	INR = 1.1	WBC = 9.5	Bill = TIT
MOCK 9	PTT = 29	PLT = 115	CRP = 4.9	V1
HCA = 18	INR = 1.1		AST = 29.0	K = 0
			ALT = 24	Angiase 1.8
			ALP = 106	Lipase 0.5
				ATB = 1



- On 8/1 following lack of recovery and maintenance of unstable hemodynamic state, the patient was unfortunately expired probably as a result of DIC or severe End organ failure due to acute Necrotizing pancreatitis.

Signature of Nurses	Signature of Physician	دستورات Orders	ساعت Time	تاریخ Date
---------------------	------------------------	-------------------	--------------	---------------

بیمار ۹۹ در ساعت ۷:۲۰ از بیمارستان

۱۸:۱۰ ۱۴/۸/۱۳۸۵

بیمار بر بالین بیمارستان

بیمار با علائم قلبی از نوعی پرستش AHA

انجام تست پکتورال فلوئید ترشید

بیمار در حال حاضر در ساعت

۱۸:۱۰
۱۸:۱۰

۱۸:۱۰ تست ترشید

بیمار ۹۹ در ساعت ۱۷:۲۰ با نام بیمارستان

۱۸:۱۰ ۱۳/۸/۱۳۸۵

بیمار فاقد نشانه‌های حیاتی و در حال سوزن بود با نام بیمارستان
بیمار فاقد نشانه‌های حیاتی و در حال سوزن بود با نام بیمارستان
بیمار فاقد نشانه‌های حیاتی و در حال سوزن بود با نام بیمارستان

بیمار با علائم قلبی از نوعی پرستش AHA 2020 انجام شد
بیمار با علائم قلبی از نوعی پرستش AHA 2020 انجام شد
بیمار با علائم قلبی از نوعی پرستش AHA 2020 انجام شد

۱۸:۱۰
۱۸:۱۰

(1) Fat ECG

بیمارستان

AGENDA

Case Presentation

What is the definition, prevalence and cause of pancreatitis due to hyper TG ?

Treatment of pancreatitis due to hyper TG

What is the time of plasma pheresis in this situation?

What is the rate of mortality in similar cases?

What is the Abdominal compartment syndrom?

PROBLEM LIST

- 42 yrs. old woman
- Acute Abdominal pain
- Severe Hyper Tg (~9150)
- Hx of DM , HTN , HLP
- Melena ?
- Uncontrol BS
- Azotemia due to high IAP

- Which type of Hypertriglyceridemia is more probable in this case ?



Frederickson classification of lipid disorders

Frederickson phenotype	Lipoprotein abnormality	Typical lipid levels
I	Chylomicrons	TG >99 th percentile
IIa	LDL	TC >90 th percentile; depending upon type, may also see apolipoprotein B ≥90 th percentile
IIb	LDL and VLDL	Depending upon type, TC and/or TG ≥90 th percentile and apolipoprotein B ≥90 th percentile
III	Remnants of VLDL and chylomicrons	TC and TG >90 th percentile
IV	VLDL	TC >90 th percentile; depending upon type, may also see TG >90 th percentile or low HDL
V	Chylomicrons and VLDL	TG >99 th percentile

TG: triglycerides; TC: total cholesterol; LDL: low-density lipoprotein; VLDL: very low-density lipoprotein; HDL: high-density lipoprotein.

Genetic contributions to hypertriglyceridemia

A. Severe HTG (TG >10 mmol/L)

Monogenic chylomicronaemia (formerly HLP type 1 or familial chylomicronaemia syndrome)

- Lipoprotein lipase deficiency (Bi-allelic *LPL* gene mutations)
- Apo C-II deficiency (Bi-allelic *APOC2* gene mutations)
- Apo A-V deficiency (Bi-allelic *APOA5* gene mutations)
- Lipase maturation factor 1 deficiency (Bi-allelic *LMF1* gene mutations)
- GPIHBP1 deficiency (Bi-allelic *GPIHBP1* gene mutations)

Multifactorial or polygenic chylomicronaemia (formerly HLP type 5)

- Complex genetic susceptibility, **including**
 - Heterozygous rare large-effect gene variants for monogenic chylomicronaemia (see above); **and/or**
 - Accumulated common small-effect TG-raising polymorphisms (eg, numerous GWAS loci including *APOA1-C3-A4-A5*; *TRIB1*, *LPL*, *MLXIPL*, *GCKR*, *FADS1-2-3*, *NCAN*, *APOB*, *PLTP*, *ANGPTL3*)
- Other
 - Transient infantile HTG (glycerol-3-phosphate dehydrogenase 1 deficiency) from bi-allelic *GPD1* gene mutations

B. Mild to moderate HTG (TG 2.0 to 9.9 mmol/L)

Multifactorial or polygenic HTG (formerly HLP type 4 or familial HTG)

- Complex genetic susceptibility (see above)

Dysbetalipoproteinaemia (formerly HLP type 3 or dysbetalipoproteinaemia)


- Complex genetic susceptibility (see above), **plus**
- *APOE* E2/E2 homozygosity **or**
- *APOE* dominant rare variant heterozygosity

Combined hyperlipoproteinaemia (formerly HLP type 2B or familial combined hyperlipidaemia)

Hypertriglyceridemia-induced pancreatitis (HTGP) causes 1 to 35 percent of all cases of acute pancreatitis and up to 56 percent of pancreatitis cases during pregnancy

The risk of acute pancreatitis increases progressively with serum triglyceride levels over 500 mg/dL (5.6 mmol/L), with the risk increasing *markedly* with levels over 1000 mg/dL

The degree of triglyceride elevation is associated with the severity of acute pancreatitis



Blood sample from a patient with a triglyceride level of 1200 mg/dL in a serum separator tube

Reprinted by permission from: Macmillan Publishers Ltd. Tsuang W, Navaneethan U, Ruiz L, et al. Hypertriglyceridemic pancreatitis: Presentation and management. Am J Gastroenterol 2009; 104:984. Copyright © 2009.

However, other factors such as the pancreatic lipase activity, the efficiency of clearing fatty acid (FA) from the serum, and the severity of the underlying pancreatic injury are also likely to influence the severity of acute pancreatitis

Eruptive xanthomata



Xanthomata are seen on the extensor surface of the forearm in a patient with severe hypertriglyceridemia.

Stratified analysis and clinical significance of elevated serum triglyceride levels in early acute pancreatitis: a retrospective study.

AU

Wan J, He W, Zhu Y, Zhu Y, Zeng H, Liu P, Xia L, Lu N

SO

Lipids Health Dis. 2017;16(1):124. Epub 2017 Jun 27

ETIOLOGY

Both primary (genetic) and secondary disorders of lipoprotein metabolism are associated with hypertriglyceridemia-induced pancreatitis

Familial chylomicronemia often presents in infancy. It is caused by a reduction in lipoprotein lipase (LPL) activity either due to deficiencies in the *LPL* gene product or *LPL* regulator encoded by *APOC2*, *APOA5*, *GPIHBP1*, and *LMF1* genes or complex genetic risks

*Patients with familial chylomicronemia can present with acute pancreatitis in the absence of an exacerbating condition. The disease frequently manifests **early in life**, but the diagnosis is often delayed and the median age of diagnosis is 24 years*

Patients develop acute pancreatitis that progresses to recurrent acute pancreatitis and chronic pancreatitis



HTGP is often precipitated by alcohol and a large fatty meal or initiation of a medication that causes HTG

Patients with mixed hyperlipidemia (high chylomicrons and VLDL) have a high risk of acute pancreatitis. However, patients with mixed hyperlipidemia do not have sufficiently elevated serum triglyceride levels to cause acute pancreatitis in the absence of contributing environmental or hormonal factors.

Secondary hypertriglyceridemia — Various conditions can raise triglycerides and lead to HTGP, especially in individuals with underlying genetic risk

- **Diabetes mellitus**
- **Medications – Hormone supplementation** with oral estrogen and selective estrogenreceptor modulator, tamoxifen, can raise serum triglyceride levels
- Other medications associated with elevated serum triglyceride levels include **clomiphene, protease inhibitors, antiretroviral agents, propofol, olanzapine, mirtazapine, retinoids, thiazide diuretics, and beta-blockers**

- **Pregnancy – Although pregnancy causes an increase in serum triglycerides that peaks in the third trimester, the total serum triglyceride level rarely exceeds 300 mg/dL (3.3mmol/L), a concentration that is not sufficient to cause acute pancreatitis.**
- **Alcohol – Alcohol may elevate triglyceride levels in patients with an underlying genetic hyperlipidemia In most other patients, triglyceride elevations with alcohol intake are transient and likely to be an epiphenomenon rather than a cause of pancreatitis**

*Lipid intolerance does not account for susceptibility to alcoholic and gallstone pancreatitis.
AU
Haber PS, Wilson JS, Apte MV, Hall W, Goumas K, Pirola RC
SO
Gastroenterology. 1994;106(3):742*



Assessment for worrisome features — Worrisome features in patients with HTGP include the following:

- Hypocalcemia
- Lactic acidosis

Signs of worsening systemic inflammation

Triglycerides themselves do not appear to be toxic. Rather, it is the breakdown of triglycerides into toxic fatty acids (FA) by pancreatic lipases that is the cause of lipotoxicity during acute pancreatitis

- The severity of acute pancreatitis in patients with hypertriglyceridemia (HTG) is dependent on both the inflammatory response caused by pancreatitis itself, plus the injury caused by lipotoxicity from triglyceride hydrolysis.
- Pancreatitis does not cause hypertriglyceridemia directly. It is possible that in some patients (body mass index [BMI] >40) the stress of a severe inflammatory response to acute pancreatitis will cause some level of triglyceride increase, but dietary indiscretion prior to the onset of acute pancreatitis cannot be excluded.


INITIAL MANAGEMENT

Management of patients with hyper triglyceridemia-induced pancreatitis (HTGP) includes treatment of acute pancreatitis (Initial therapy including bowel rest, intravenous fluids, and symptomatic treatment should be initiated

reduction of serum triglyceride levels with the goal of preventing necrotizing pancreatitis and organ failure. In patients with HTGP, maintenance of triglyceride levels below 500 mg/dL (5.6 mmol/L) may expedite clinical improvement

Hypertriglyceridemia-induced pancreatitis: updated review of current treatment and preventive strategies.
AU
Rawla P, Sunkara T, Thandra KC, Gaduputi V
SO
Clin J Gastroenterol. 2018;11(6):441. Epub 2018 Jun 1

Approach to the management of the adult patient with hypertriglyceridemic pancreatitis



**Insulin — We administer intravenous (IV) insulin in patients with worrisome features of HTGP in whom plasmapheresis is indicated but is unavailable or cannot be tolerated. As insulin can decrease both triglyceride and glucose levels, we also administer insulin inpatients with HTGP with diabetes to manage hyperglycemia :
plasma glucose >180 mg/dL**

[PubMed](#)

TI

Insulin can be used to treat severe hypertriglyceridaemia in pregnant women without diabetes.

AU

Ali AS

SO

BMJ Case Rep. 2021;14(7) Epub 2021 Jul 21.

Insulin decreases VLDL triglyceride production and also lowers serum triglyceride levels by enhancing lipoprotein lipase (LPL) activity, an enzyme that accelerates chylomicron and VLDL metabolism to glycerol and fatty free acids (FFAs)

Insulin also **inhibits hormone-sensitive lipase** in adipocytes, which is the key enzyme for breaking down adipocyte , triglyceride and releasing fatty acids (FAs) into the circulation. Insulin lowers triglyceride levels, but the goal of insulin therapy in severe acute pancreatitis associated with severe HTG is to reverse the stress-associated release of FAs from adipocytes.

Hyperglycemic crises in adult patients with diabetes.

AU

Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN

SO

Diabetes Care. 2009;32(7):133

- In patients with worrisome features of HTGP, we typically initiate an IV infusion of regular insulin at a rate of 0.1 to 0.3 units/kg/hour while closely monitoring blood glucose levels. Inpatients with blood glucose levels between 150 and 200 mg/dL, we administer a separate 5percent dextrose infusion to prevent hypoglycemia due to the insulin infusion. Triglyceride levels should be monitored every 12 hours
- IV insulin should be stopped when triglyceride levels are <500 mg/dL (5.6 mmol/L).
- IV insulin may be more effective than subcutaneous insulin in severe cases of HTGP and is easier to titrate than subcutaneous administration of insulin

Additional measures in selected patients

Plasmapheresis

Evidence to support the use of plasmapheresis in patients with HTGP is from observational studies; randomized trials are lacking

A single session of plasmapheresis has been reported to lower triglyceride levels by 50 to 80 percent. However, studies have not demonstrated an improvement in outcomes in patients with HTGP. One prospective study of plasmapheresis, which examined 60 patients with HTGP who underwent plasmapheresis, found no statistical difference in mortality and local complications between those who received plasmapheresis and historical controls

However, the benefit of early initiation of plasmapheresis has not been consistently demonstrated

Factors affecting outcome in acute hypertriglyceridemic pancreatitis treated with plasma exchange: an observational cohort study.

AU

Gubensek J, Buturovic-Ponikvar J, Romozi K, Ponikvar R

SO

PLoS One. 2014;9(7):e102748. Epub 2014 Jul 2

Plasmapheresis does not appear to improve outcomes in uncomplicated cases of HTGP (?)

In one study that included 67 patients without multi organ dysfunction, there was no significant benefit to either mortality or length of stay with the use of plasmapheresis to medical management, even when patients presented with high levels of triglycerides (>1000)

plasmapheresis should be continued until triglyceride levels are below <1000 mg/dL (11.3 mmol/L)

Another Study :

Plasmapheresis (PEX) rapidly removes TGs and chylomicron from the circulation removing the inciting factor and halting the further inflammation and damage to the pancreas.

PEX lowers the lipid levels drastically within hours compared to conservative therapy that usually takes several days to achieve the same reduction in TG levels.

Most patients require only one session of PEX as it is reported to lower TG levels by 50-80%.

Outcomes not only by lowering TG levels but also by removing Pro inflammatory markers and cytokines to down regulate the inflammatory process in HTG-AP

Although multiple case series report the benefit of PEX in management of HTG-AP, the only prospective study to date with a historic control (60 versus 34 patients) failed to show any mortality benefit compared to conservative management.

J.-H. Chen, J.-H. Yeh, H.-W. Lai, and C.-S. Liao, "Therapeutic plasma exchange in patients with hyperlipidemic pancreatitis," *World Journal of Gastroenterology*, vol. 10, no. 15, pp. 2272-2274, 2004.

However, another recent large retrospective study including 111 patients treated with PEX also found no mortality benefit in patients who received early PEX (within 36 hours) versus late PEX (>36 hours) for HTG-AP

The authors also reported a significantly lower mortality in patients who received citrate anticoagulation (1%) during PEX compared to heparin anticoagulation (11%) ($P = 0.04$); however, 24% patients in heparin group had severe pancreatitis as compared to citrate group (14%) but the difference was not statistically significant

J.Gubensek, J. Buturovic-Ponikvar, K. Romozi, and R. Ponikvar, "Factors affecting outcome in acute hypertriglyceridemic pancreatitis treated with plasma exchange: An observational cohort study," *PLoS ONE*, vol. 9, no. 7, Article ID e102748, 2014.

High-Volume Hemofiltration (HVHF) and Hemoperfusion (HP)

Continuous venovenous filtration is commonly used for severe acute pancreatitis and has shown good results including mortality benefit; however roles of hemofiltration in HTG-AP have been recently explored. Mao et al. in 2003 studied the role of hemofiltration in HTG-AP by employing hemofiltration in patient with HTG induced severe acute pancreatitis

E.-Q. Mao, Y.-Q. Tang, and S.-D. Zhang, "Formalized therapeutic guideline for hyperlipidemic severe acute pancreatitis," *World Journal of Gastroenterology*, vol. 9, no. 11, pp. 2622–2626, 2003.

High-Volume Hemofiltration (HVHF) and Hemoperfusion (HP)

There was statistically significant reduction of serum TGs, IL-10, and APACHE II score with no mortality in severe acute pancreatitis patients

E.-Q. Mao, Y.-Q. Tang, and S.-D. Zhang, "Formalized therapeutic guideline for hyperlipidemic severe acute pancreatitis," *World Journal of Gastroenterology*, vol. 9, no. 11, pp. 2622–2626, 2003.

Heparin releases stored lipoprotein lipase from the endothelial cell thus lowering TGs levels. Combination of insulin and heparin has been used to lower TGs level in case reports and case series with mean decrease of TGs level by 50% within 24 hours

D. Jain and J. Zimmerschied, "Heparin and insulin for hypertriglyceridemia-induced pancreatitis: case report," *TheScientific World Journal*, vol. 9, pp. 1230-1232, 2009.

P. Jain, R. R. Rai, H. Udawat, S. Nijhawan, and A. Mathur, "Insulin and heparin in treatment of hypertriglyceridemia-induced pancreatitis," *World Journal of Gastroenterology*, vol. 13, no. 18, pp. 2642-2643, 2007.

Continuous intravenous heparin administration in humans causes a decrease in serum lipolytic activity and accumulation of chylomicrons in circulation.
AU
Weintraub M, Rassin T, Eisenberg S, Ringel Y, Grosskopf I, Iaina A, Charach G, Liron M, Rubinstein A
SO
J Lipid Res. 1994;35(2):229

There is a concern of rebound hypertriglyceridemia as long term or continuous heparin infusion has been shown to deplete LPL, leading to reduction of chylomicrons catabolism and increase in TGs levels.

Low molecular weight heparin has also been shown to lower LPLs level similar to conventional unfractionated heparin infusion due to concern of rebound hypertriglyceridemia and risk of hemorrhage into the pancreas during acute attack on continuous heparin infusion, heparin should preferably be Avoided in some cases.

B. Nasstrom, B. G. Stegmayr, G. Olivecrona, and T. Olivecrona, "Lower plasma levels of lipoprotein lipase after infusion of low molecular weight heparin than after administration of conventional heparin indicate more rapid catabolism of the enzyme," *Journal of Laboratory and Clinical Medicine*, vol. 142, no. 2, pp. 90-99, 2003.

Combined Blood Purification Therapy (CBPT)

CBPT is a two-step approach for management of acute severe pancreatitis involving plasmapheresis and continuous venous hemofiltration. Coupled plasma filtration adsorption combined with CVVH has been shown to improve mortality and lowering of inflammatory markers in severe acute pancreatitis irrespective of etiology of pancreatitis

C.He, L. Zhang, W. Shi et al., "Coupled plasma filtration adsorption combined with continuous veno-venous hemofiltration treatment in patients with severe acute pancreatitis," *Journal of Clinical Gastroenterology*, vol. 47, no. 1, pp. 62-68, 2013.

Lipid management — Patients recovering from HTGP require long-term therapy to prevent recurrent acute pancreatitis and to prevent other complications of HTG

This consists of both pharmacologic therapy (oral gemfibrozil 600 mg twice daily) and dietary modification with restriction of fat content to 10 to 15 percent of the diet and avoidance of concentrated sugars. Other non pharmacologic interventions include weight loss in patients who are obese, aerobic exercise, avoidance of medications that raise serum triglyceride levels, and strict glycemic control in diabetics.

AGENDA

Case Presentation

What is the definition, prevalence and cause of pancreatitis due to hyper TG ?

Treatment of pancreatitis due to hyper TG

What is the time of plasma pheresis in this situation?

What is the rate of mortality in similar cases?


What is the Abdominal compartment syndrom?

abdominal compartment syndrome in acute pancreatitis


There was a clear correlation between the maximum IAP value within the first 2 weeks and the mortality rate. Also Pupelis et al. found that in patients with IAP higher than 25 mmHg had a significantly increased mortality up to 36%

Pupelis G, Austrums E, Snippe K, Berzins M. Clinical significance of increased intraabdominal pressure in severe acute pancreatitis. *Acta Chirurgica Belgica* 2002;102:71-74.

Measurement of intra-abdominal pressure



Intra-abdominal hypertension and abdominal compartment syndrome



Intra-abdominal hypertension (IAH) is defined as a sustained intra-abdominal pressure >12 mmHg. Abdominal compartment syndrome (ACS) is defined as a sustained intra-abdominal pressure >20 mmHg that is associated with new organ dysfunction.

Intra-abdominal hypertension is increasingly reported in patients with severe acute pancreatitis, and is caused by several factors, including visceral edema and ascites associated with massive fluid resuscitation, paralytic ileus and retroperitoneal inflammation. Several reports conclude that this phenomenon occurs within the first 5 days after admission.

Although the typical symptoms of ACS, i.e. rapidly evolving multiple organ dysfunction syndrome (MODS) most often a combination of respiratory failure, hemodynamic compromise and acute renal failure) are often found in patients with severe acute

Pancreatitis

IAH may also contribute to the development of pancreatic necrosis


Systemic effects of elevated intra-abdominal pressure

Central nervous system	Gastrointestinal
↑ Intracranial pressure	↓ Celiac blood flow
↓ Cerebral perfusion pressure	↓ SMA blood flow
Cardiac	↓ Mucosal blood flow
Hypovolemia	↓ pHi
↓ Cardiac output	Renal
↓ Venous return	↓ Urinary output
↑ PCWP and CVP	↓ Renal blood flow
↑ SVR	↓ GFR
Pulmonary	Hepatic
↑ Intrathoracic pressure	↓ Portal blood flow
↑ Peak inspiratory pressure	↓ Mitochondrial function
↑ Airway pressures	↓ Lactate clearance
↓ Compliance	Abdominal wall
↓ PaO ₂	↓ Compliance
↑ PaCO ₂	↓ Rectus sheath blood flow
↑ Shunt fraction	
↑ Vd/Vt	

The association between IAH and development of organ dysfunction in severe acute pancreatitis is well documented. De Waele et al. showed that there was a 95% incidence of respiratory failure, 91% cardiovascular and 86% acute renal failure rate in patients with IAP of 15 mmHg or higher

Decompressive laparotomy has been shown to effectively reduce IAP and reverse the symptoms typically associated with ACS but mortality is high

De Waele JJ, Hoste E, Blot SI, Decruyenaere J, Colardyn F. Intraabdominal hypertension in patients with severe acute pancreatitis Crit Care 2005;9:R452-7.



<https://doi.org/10.1016/j.jviscsurg.2021.01.001>
1878-7886/© 2021
Elsevier Masson SAS.
All rights reserved.



Thank you